JP2016506912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506912A5 JP2016506912A5 JP2015553074A JP2015553074A JP2016506912A5 JP 2016506912 A5 JP2016506912 A5 JP 2016506912A5 JP 2015553074 A JP2015553074 A JP 2015553074A JP 2015553074 A JP2015553074 A JP 2015553074A JP 2016506912 A5 JP2016506912 A5 JP 2016506912A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- pharmaceutical composition
- fgfr3
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2013/001480 | 2013-01-16 | ||
| PCT/IB2013/001480 WO2014111744A1 (en) | 2013-01-16 | 2013-01-16 | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
| PCT/EP2014/050800 WO2014111467A1 (en) | 2013-01-16 | 2014-01-16 | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019021752A Division JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506912A JP2016506912A (ja) | 2016-03-07 |
| JP2016506912A5 true JP2016506912A5 (enExample) | 2017-02-16 |
Family
ID=48289519
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553175A Withdrawn JP2016506914A (ja) | 2013-01-16 | 2013-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| JP2015553074A Withdrawn JP2016506912A (ja) | 2013-01-16 | 2014-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
| JP2019021752A Expired - Fee Related JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553175A Withdrawn JP2016506914A (ja) | 2013-01-16 | 2013-01-16 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019021752A Expired - Fee Related JP6995069B2 (ja) | 2013-01-16 | 2019-02-08 | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20150344855A1 (enExample) |
| EP (2) | EP2945967B1 (enExample) |
| JP (3) | JP2016506914A (enExample) |
| KR (3) | KR20160002681A (enExample) |
| CN (1) | CN105121464B (enExample) |
| AU (2) | AU2013373679A1 (enExample) |
| CA (2) | CA2898415A1 (enExample) |
| DK (1) | DK2945967T3 (enExample) |
| EA (2) | EA201591324A1 (enExample) |
| ES (1) | ES2796743T3 (enExample) |
| HU (1) | HUE049556T2 (enExample) |
| IL (2) | IL239810A0 (enExample) |
| MX (2) | MX372787B (enExample) |
| PE (1) | PE20151664A1 (enExample) |
| PL (1) | PL2945967T3 (enExample) |
| PT (1) | PT2945967T (enExample) |
| SG (2) | SG11201505488XA (enExample) |
| SI (1) | SI2945967T1 (enExample) |
| WO (2) | WO2014111744A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150344855A1 (en) | 2013-01-16 | 2015-12-03 | INSERM (Institut National de la Santé et de la Recherche Médicale | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders |
| CA2972865A1 (en) * | 2015-01-07 | 2016-07-14 | Therachon Sas | Soluble fgfr3 decoys for treating skeletal growth disorders |
| KR101894022B1 (ko) * | 2016-04-25 | 2018-08-31 | 장부다 | Vr 공간을 제공하는 디바이스를 이용한 결제 방법 및 그 디바이스 |
| KR102432192B1 (ko) * | 2016-07-07 | 2022-08-12 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도 |
| EP3684394A1 (en) * | 2017-09-20 | 2020-07-29 | Pfizer Inc. | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
| CN108410803B (zh) * | 2018-03-28 | 2019-02-05 | 湖南源品细胞生物科技有限公司 | 一种诱导脂肪干细胞成软骨分化的培养方法和培养液 |
| CN110272900B (zh) * | 2019-04-19 | 2024-03-26 | 中国人民解放军陆军军医大学 | 用于制备骨骼发育异常猪模型的sgRNA及其应用 |
| WO2022106976A1 (en) | 2020-11-18 | 2022-05-27 | Pfizer Inc. | Stable pharmaceutical formulations of soluble fgfr3 decoys |
| JP2022184798A (ja) | 2021-06-01 | 2022-12-13 | ファイザー・インク | ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| WO1996041523A1 (en) * | 1995-06-12 | 1996-12-27 | Yeda Research And Development Co., Ltd. | Fgf9 as a specific ligand for fgfr3 |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| US20040109850A1 (en) * | 2000-12-18 | 2004-06-10 | Neelam Jaiswal | Treatment of bone disorders by modulation of fgfr3 |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
| JP2003104908A (ja) * | 2001-09-28 | 2003-04-09 | Ichikazu Nakao | 軟骨無形成症治療剤 |
| US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
| IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| AU2005216547B2 (en) * | 2004-02-24 | 2009-03-12 | Allergan, Inc. | Botulinum toxin screening assays |
| NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| US8962556B2 (en) | 2006-09-28 | 2015-02-24 | Prochon Biotech Ltd. | FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof |
| PE20081250A1 (es) | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
| WO2008133873A2 (en) * | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| WO2010002862A2 (en) | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| CN102171343B (zh) | 2008-08-04 | 2017-07-14 | 戊瑞治疗有限公司 | Fgfr细胞外结构域酸性区突变蛋白 |
| AR073770A1 (es) | 2008-10-20 | 2010-12-01 | Imclone Llc | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
| ES2549769T3 (es) | 2009-03-25 | 2015-11-02 | Genentech, Inc. | Anticuerpos anti-FGFR3 y métodos que emplean los mismos |
| CN101585866B (zh) * | 2009-07-02 | 2011-10-05 | 中国人民解放军第三军医大学野战外科研究所 | 调节fgfr3活性的多肽及其筛选方法和应用 |
| WO2011034940A1 (en) | 2009-09-15 | 2011-03-24 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr4 extracellular domains |
| PT2498799T (pt) | 2009-11-13 | 2016-11-04 | Five Prime Therapeutics Inc | Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2 |
| WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
| WO2011088196A2 (en) | 2010-01-14 | 2011-07-21 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP6055779B2 (ja) * | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| CN102219860B (zh) | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| CA2853358A1 (en) | 2011-10-24 | 2013-05-02 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| CA2880013C (en) | 2012-07-24 | 2022-11-29 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| BR112015001724A2 (pt) | 2012-07-27 | 2018-04-03 | Genentech Inc | métodos de tratamento de condições relacionadas a fgfr3 |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| US20150344855A1 (en) | 2013-01-16 | 2015-12-03 | INSERM (Institut National de la Santé et de la Recherche Médicale | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders |
| RS60593B1 (sr) | 2014-01-24 | 2020-08-31 | Ngm Biopharmaceuticals Inc | Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu |
| CA2972865A1 (en) | 2015-01-07 | 2016-07-14 | Therachon Sas | Soluble fgfr3 decoys for treating skeletal growth disorders |
| KR102432192B1 (ko) | 2016-07-07 | 2022-08-12 | 화이자 인코포레이티드 | 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도 |
| EP3684394A1 (en) | 2017-09-20 | 2020-07-29 | Pfizer Inc. | Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides |
-
2013
- 2013-01-16 US US14/759,490 patent/US20150344855A1/en not_active Abandoned
- 2013-01-16 JP JP2015553175A patent/JP2016506914A/ja not_active Withdrawn
- 2013-01-16 KR KR1020157022203A patent/KR20160002681A/ko not_active Withdrawn
- 2013-01-16 CA CA2898415A patent/CA2898415A1/en not_active Abandoned
- 2013-01-16 WO PCT/IB2013/001480 patent/WO2014111744A1/en not_active Ceased
- 2013-01-16 AU AU2013373679A patent/AU2013373679A1/en not_active Abandoned
- 2013-01-16 EA EA201591324A patent/EA201591324A1/ru unknown
- 2013-01-16 SG SG11201505488XA patent/SG11201505488XA/en unknown
-
2014
- 2014-01-16 EP EP14702206.5A patent/EP2945967B1/en active Active
- 2014-01-16 MX MX2015009142A patent/MX372787B/es active IP Right Grant
- 2014-01-16 SG SG11201505140XA patent/SG11201505140XA/en unknown
- 2014-01-16 PT PT147022065T patent/PT2945967T/pt unknown
- 2014-01-16 PL PL14702206T patent/PL2945967T3/pl unknown
- 2014-01-16 SI SI201431607T patent/SI2945967T1/sl unknown
- 2014-01-16 AU AU2014206844A patent/AU2014206844A1/en not_active Abandoned
- 2014-01-16 KR KR1020217013228A patent/KR20210054026A/ko not_active Withdrawn
- 2014-01-16 EA EA201591055A patent/EA201591055A1/ru unknown
- 2014-01-16 WO PCT/EP2014/050800 patent/WO2014111467A1/en not_active Ceased
- 2014-01-16 EP EP20167861.2A patent/EP3736285A1/en not_active Withdrawn
- 2014-01-16 HU HUE14702206A patent/HUE049556T2/hu unknown
- 2014-01-16 DK DK14702206.5T patent/DK2945967T3/da active
- 2014-01-16 US US14/759,535 patent/US10724014B2/en not_active Expired - Fee Related
- 2014-01-16 CN CN201480005077.6A patent/CN105121464B/zh not_active Expired - Fee Related
- 2014-01-16 PE PE2015001353A patent/PE20151664A1/es not_active Application Discontinuation
- 2014-01-16 KR KR1020157022078A patent/KR102249454B1/ko not_active Expired - Fee Related
- 2014-01-16 JP JP2015553074A patent/JP2016506912A/ja not_active Withdrawn
- 2014-01-16 ES ES14702206T patent/ES2796743T3/es active Active
- 2014-01-16 CA CA2896978A patent/CA2896978A1/en active Pending
-
2015
- 2015-07-06 IL IL239810A patent/IL239810A0/en unknown
- 2015-07-15 MX MX2019013857A patent/MX2019013857A/es unknown
- 2015-07-16 IL IL239996A patent/IL239996A0/en unknown
-
2019
- 2019-02-08 JP JP2019021752A patent/JP6995069B2/ja not_active Expired - Fee Related
- 2019-08-05 US US16/532,184 patent/US20200199545A1/en not_active Abandoned
-
2020
- 2020-03-13 US US16/818,954 patent/US11702642B2/en active Active
- 2020-06-19 US US16/906,046 patent/US11814654B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2607365C2 (ru) | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение | |
| CN104507492B (zh) | 治疗高脂血症的包含泌酸调节肽衍生物的组合物 | |
| JP2011526886A5 (enExample) | ||
| JP2016506914A5 (enExample) | ||
| US20170088598A1 (en) | Long-acting oxyntomodulin variants and methods of producing same | |
| HRP20221021T1 (hr) | T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02 | |
| JP2013518115A5 (enExample) | ||
| JP2016518351A5 (enExample) | ||
| AU2012261869A1 (en) | Long-acting GLP-1/Glucagon receptor agonists | |
| JP2016527249A5 (enExample) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| NO326298B1 (no) | Anvendelse av R'-Glu-Trp-R'' dipeptider i fremstilling av medikamenter | |
| JP2015520184A (ja) | ペグ化ｏｘｍ変異体 | |
| JP2016512213A5 (enExample) | ||
| JP2013518090A5 (enExample) | ||
| ES2319454T9 (es) | Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK | |
| JP2014050390A5 (enExample) | ||
| JP2017532965A (ja) | 抗血管新生活性を有するシンデカン−２のフラグメント | |
| US20220287347A1 (en) | Peptides for treating muscle atrophy | |
| CN109328069A (zh) | Il-22在治疗坏死性小肠结肠炎中的用途 | |
| AU2019364063A1 (en) | Pharmaceutical composition for treating aplastic anemia | |
| CA2716565C (en) | Pharmaceutical composition for transnasal administration | |
| JP6615504B2 (ja) | 高血圧症の予防又は治療用医薬 | |
| JP2012529423A5 (enExample) | ||
| EP2894161B1 (en) | Peptide for inhibiting vascular endothelial growth factor receptor |